Baricitinib
‘Recovery Trial’ finds anti-arthritis drug reduces severe COVID-19 mortality
The trial found that Baricitinib reduces the mortality of hospitalized patients by 13%. Baricitinib inhibits the enzymes of a specific family of enzyme called the Janus Kinase (JAK) family
Make WHO-recommended new COVID-19 drugs accessible, affordable, demands MSF
US pharma giant Eli Lilly has the patent for Baricitinib, which will affect its availability and accessibility. MSF has called on governments to take immediate steps to ensure that patent monopolies do not stand in the way of access to this drug
Equitable access to Covid-19 diagnostics and therapeutics is key to ending the pandemic
One year has passed since the TRIPS waiver proposal was first tabled at the World Trade Organization, and rich countries persevere in opposing it. This has affected the availability of vaccines, and is having effect on access to diagnostics and therapeutics too
